219 related articles for article (PubMed ID: 15638956)
1. Effect of epidermal growth factor receptor mutations on the response to epidermal growth factor receptor tyrosine kinase inhibitors: target-based populations for target-based drugs.
Calvo E; Rowinsky EK
Clin Lung Cancer; 2004 Dec; 6 Suppl 1():S35-42. PubMed ID: 15638956
[TBL] [Abstract][Full Text] [Related]
2. Predictors of sensitivity and resistance to epidermal growth factor receptor inhibitors.
Perea S; Hidalgo M
Clin Lung Cancer; 2004 Dec; 6 Suppl 1():S30-4. PubMed ID: 15638955
[TBL] [Abstract][Full Text] [Related]
3. Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors.
Juchum M; Günther M; Laufer SA
Drug Resist Updat; 2015 May; 20():12-28. PubMed ID: 26021435
[TBL] [Abstract][Full Text] [Related]
4. Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer.
De Luca A; Normanno N
Curr Drug Targets; 2010 Jul; 11(7):851-64. PubMed ID: 20388064
[TBL] [Abstract][Full Text] [Related]
5. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
Chung C
J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer: impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors.
Cohen V; Agulnik JS; Ang C; Kasymjanova G; Batist G; Small D; Brandao G; Chong G; Miller WH
Cancer; 2010 Sep; 116(18):4309-17. PubMed ID: 20549828
[TBL] [Abstract][Full Text] [Related]
8. [Clinical research and drug review of epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer].
Zhou M; Chen DM; Xia L; Song YY; Shi YK; Yang ZM
Zhonghua Zhong Liu Za Zhi; 2019 Dec; 41(12):949-952. PubMed ID: 31874554
[TBL] [Abstract][Full Text] [Related]
9. Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer.
Iwama E; Nakanishi Y; Okamoto I
Expert Rev Anticancer Ther; 2018 Mar; 18(3):267-276. PubMed ID: 29363369
[TBL] [Abstract][Full Text] [Related]
10. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
11. Epidermal Growth Factor Receptor targeting in non-small cell lung cancer: revisiting different strategies against the same target.
Castañón E; Martín P; Rolfo C; Fusco JP; Ceniceros L; Legaspi J; Santisteban M; Gil-Bazo I
Curr Drug Targets; 2014; 15(14):1273-83. PubMed ID: 25511613
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
Roengvoraphoj M; Tsongalis GJ; Dragnev KH; Rigas JR
Cancer Treat Rev; 2013 Dec; 39(8):839-50. PubMed ID: 23768755
[TBL] [Abstract][Full Text] [Related]
13. Addressing epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer.
Noda S; Kanda S
Expert Rev Respir Med; 2016; 10(5):547-56. PubMed ID: 26959310
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations.
Sakurada A; Shepherd FA; Tsao MS
Clin Lung Cancer; 2006 May; 7 Suppl 4():S138-44. PubMed ID: 16764754
[TBL] [Abstract][Full Text] [Related]
15. [The concomitant gene alterations impact the therapeutic efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with epidermal growth factor receptor sensitive mutation].
Li JM; Hu J; Bai CX; Zhang Y; Xu XB; Wang XD; Ding N
Zhonghua Jie He He Hu Xi Za Zhi; 2018 Oct; 41(10):778-782. PubMed ID: 30347549
[No Abstract] [Full Text] [Related]
16. Highly sensitive and noninvasive detection of epidermal growth factor receptor T790M mutation in non-small cell lung cancer.
He C; Zheng L; Xu Y; Liu M; Li Y; Xu J
Clin Chim Acta; 2013 Oct; 425():119-24. PubMed ID: 23886554
[TBL] [Abstract][Full Text] [Related]
17. Treatment of nonsmall cell lung cancer: overcoming the resistance to epidermal growth factor receptor inhibitors.
Carter CA; Giaccone G
Curr Opin Oncol; 2012 Mar; 24(2):123-9. PubMed ID: 22314615
[TBL] [Abstract][Full Text] [Related]
18. Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer.
Chen L; Fu W; Zheng L; Liu Z; Liang G
J Med Chem; 2018 May; 61(10):4290-4300. PubMed ID: 29136465
[TBL] [Abstract][Full Text] [Related]
19. [Mechanism and clinical efficacy of third-generation epidermal growth factor receptor tyrosine kinase inhibitor in non-small cell lung cancer].
Chen XX; Zhou CC
Zhonghua Zhong Liu Za Zhi; 2017 Jun; 39(6):401-404. PubMed ID: 28635227
[TBL] [Abstract][Full Text] [Related]
20. Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
Nurwidya F; Takahashi F; Murakami A; Kobayashi I; Kato M; Shukuya T; Tajima K; Shimada N; Takahashi K
Respir Investig; 2014 Mar; 52(2):82-91. PubMed ID: 24636263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]